A Phase 4 interventional study of Iron and EPO in Anemia, Sepsis and Septic Shock, sponsored by Piotr Czempik. Recruiting at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-27.
Sponsored by Piotr Czempik · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing iron in Anemia — 3 open to participants now, 3 under way, none of them phase 3. Iron · Anemia.
Among the 34 studies testing iron in Anemia, this one is the 19th largest by planned enrollment, is the only one that started in 2024, is one of 7 in phase 4, and was the 32nd registered.
1,812 studies on the registry are indexed under Anemia; 212 are open to participants now.
Browse Anemia studies →3 of the 34 studies testing iron in Anemia are open now, in 3 countries. Recruiting first, the newest first:
Cajal Therapeutics Inc. · Sites in Australia
Ages 18–55 · Healthy volunteers
University of Aarhus · Sites in Denmark
Ages 75+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 117 Anemia studies recruiting now, 66 (56%) set no upper age limit and 33 (28%) stop at 75 or younger; 32 take children under 18; 21 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 6 · Phase 4 7
First in 1995; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 117 across 1,338 interventional studies indexed under Anemia.
Median enrollment 275 across the 34 interventional studies. Of the 25 that completed or were terminated, 5 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 34 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Piotr Czempik as lead sponsor.
Piotr Czempik has 1 study filed under Anemia — fewer than ten, so there is no comparison to draw.
1 of the studies testing iron in Anemia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06670963Piotr CzempikUse of Epoetin Alfa and Iron Derisomaltose in Treatment of Anemia in Patients With Sepsis or Septic Shock: a Randomized Controlled Trial | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 34 studies testing iron in Anemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Background Up to 66% of have anemia at the admission to the intensive care unit. This number increases to 95% after 72 hours of hospitalization in the intensive care unit due to illness and iatrogenic blood loss. Anemia worsens tissue oxygenation, especially in patietns with sepsis or septic shock, who already have blood flow issues. Instead of giving blood transfusions, which can have side effects, we aim to address the root causes of anemia in these patients. Sepsis can cause "inflammatory anemia" and combine with iron deficiency anemia. Current anemia treatments include drugs that stimulate red blood cell production and intravenous iron supplements. Some think that iron supplements can worsen infections by feeding pathogens, but this is not conclusively proven. Since transfused red blood cells (RBC) also contain iron, small doses of intravenous iron might help sepsis patients with iron deficiency.
There is a need for a study on the effects of epoetin alfa and iron derisomaltose on hemoglobin (Hb) levels in sepsis patients.
Hypothesis and Aim Treating anemia in sepsis patients could increase Hb levels and reduce RBC transfusions, improving patient outcomes. This study aims to evaluate the effects of epoetin alfa ± iron derisomaltose on Hb levels and RBC transfusion rates.
Primary Endpoints:
Secondary Endpoints:
Materials and Methods:
This will be a randomized controlled clinical trial recruting 200 patients
Inclusion Criteria:
Exclusion Criteria:
Study Group:
Control Group:
Laboratory Parameters:
Initial: interleukin-6, procalcitonin, C-reactive protein, creatinine, ammonia, blood urea nitrogen, aspartate aminotransferase, alanine aminotransferase, total bilirubin, complete blood count (CBC), reticulocytes (RET), ferritin, iron, transferrin.
Serial: CBC and RET (days 1, 3, 5, 8, 10, 12)
Project Description:
Project Title: The use of epoetin alfa and iron derisomaltose in treating anemia in patients with sepsis or septic shock in the ICU: a randomized controlled clinical trial.
Project Acronym: EpoAid
Theoretical Background and Rationale: Up to 66% of patients have anemia at admission to the intensive care unit. Additionally, many patients develop anemia during hospitalization in the intensive care unit due to illness and iatrogenic blood loss for laboratory diagnostics. After 72 hours 95% of intensive care unit patients are anemic. Anemia increases the risk of tissue oxygen deficiency, which is particularly important in sepsis or septic shock patients who may have peripheral perfusion disorders due to infection. Anemia should be treated causally because red blood cell transfusions can lead to adverse effects, including immunomodulation leading to innate immunity suppression, which is particularly significant in critically ill sepsis or septic shock patients. Anemia caused by sepsis is known as inflammatory anemia (AI). Sepsis patients often have mixed anemia, combining features of AI and iron deficiency anemia (IDA) - AI+IDA. Currently available treatments for mixed anemia include erythropoiesis-stimulating agents (ESA) and intravenous iron supplements (e.g., iron derisomaltose). Manufacturers of intravenous iron products contraindicate their use in infections since intravenous iron could theoretically exacerbate infections by stimulating pathogen growth. However, there is no conclusive data on this. Considering that stored red blood cells are also a source of iron that pathogens can use, it seems that fractional doses of intravenous iron could benefit sepsis patients with diagnosed iron deficiency. Additionally, ESA administration could cause functional iron deficiency, where small doses of intravenous iron might also be beneficial.
Attempts to use ESA and intravenous iron in the general ICU population have yielded inconclusive results due to methodological errors. In the IRONMAN study comparing iron carboxymaltose with placebo, no difference in transfusion rates (primary endpoint) was found, but higher Hb levels were observed at hospital discharge in the intervention group (107 vs. 100 g/L). This trial had some methodological flaws: intravenous iron was administered regardless of anemia etiology, red blood cell transfusion decisions were made by clinicians - there was no transfusion algorithm, and the average hospital stay was 11 days - maximal effect of intravenous iron is seen after 3-4 weeks, at least 2 weeks.
Iron deficiency diagnostics in sepsis patients must rely on parameters independent of the systemic inflammatory response since standard iron metabolism parameters (ferritin, transferrin saturation) are not useful here. Severe sepsis was an exclusion criterion in the IRONMAN study. Given the limitations of previous studies and the lack of research on the use of intravenous iron in sepsis patients, it is warranted to conduct a study evaluating the effect of epoetin alfa ± iron derisomaltose on Hb levels in sepsis or septic shock patients.
Hypothesis and Research Aim: Causal treatment of anemia in sepsis or septic shock patients may lead to increased Hb levels and reduced transfusion rates, potentially improving patient outcomes. This study aims to evaluate the effect of epoetin alfa ± iron derisomaltose on one primary and several secondary outcomes.
Materials and Methods: A randomized controlled clinical trial is planned. Blinding will be single due to the color (rusty) of the intervention drug (iron derisomaltose) and problems with complete blinding of the intervention. Randomization will be done using a computer generator of randomized numbers using block of 4. Two hundred patients will be recruited (100 in the experimental group, 100 in the control group). If a study subject starts bleeding or requires surgery (affects Hb levels and transfusion necessity - primary endpoints), the time until this event will be evaluated. Data collected: demographics (gender, age), infection site, length of stay (ICU, hospital), mortality (ICU, hospital, 30 days, 90 days). Blood loss for laboratory diagnostics will be monitored (calculation based on laboratory parameters ordered and test tube used). Pharmacological venous thromboembolism prophylaxis will be used in the experimental and contorol groups: enoxaparin 40 mg x 1 sc in patients with creatinine clearance ≥30 mL/min or dalteparin 5000 IU x 1 sc in patients with creatinine clearance \<30 mL/min, and a red blood cell transfusion decision algorithm will be employed.
Experimental group:
epoetin alfa (Binocrit, Sandoz, Poland) given intravenously when Hb \<120 g/L, dosed by a study subject weight:
Control Group:
red blood cell transfusion decision based on a proprietary decision algorithm.
Monitored parameters:
Timeline: November 2024 - December 2026
Feasibility: given the number of ICU hospitalizations (approximately 400 per year) and the prevalence of sepsis/septic shock, it will be possible to enroll about 100 patients per year.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Epoetin alfa 50 units/kg IV 3 times weekly and ferric derisomaltose 0.2g IV if reticulocyte hemoglobin equivalent \<29.3 pg
Drug: Iron · Drug: EPO
0.9% NaCl
Drug: 0.9 % NaCl
Iron derisomaltose 0.2g IV if reticulocyte hemoglobin equivalent \<29.3 pg (lower limit for the local laboratory reference range for reticulocyte hemoglobin equivalent)
Epoetin alfa 50 units/kg IV 3 times weekly
Volume of 0.9% NaCl identical as volume of medications used in experimental arm
Hemoglobin concentration difference at exit from the study
The difference between hemoglobin concentration at exit from the study and day 1 corrected for Hb increase due to possible RBC transfusion \[RBC volume x RBC Hb concentration/study subject's blood volume (weight x 65 mL for women/weight x 75 mL for men)\]
Time frame: From enrollment to day 15/death/discharge from ICU/bleeding episode/surgery whatever comes first
Hemoglobin concentration difference at 1 week
The difference in hemoglobin concentration on days 8 and 1 corrected for Hb increase due to possible RBC transfusion \[RBC volume x RBC Hb concentration/study subject's blood volume (weight x 65 mL for women/weight x 75 mL for men)\]
Time frame: From enrollment to day 8 (if a study subject still in the trial)
Hemoglobin concentration difference at 2 weeks
The difference in hemoglobin concentration between day 15 and day 1 corrected for Hb increase due to possible RBC transfusion \[RBC volume x RBC Hb concentration/study subject's blood volume (weight x 65 mL for women/weight x 75 mL for men)\]
Time frame: From enrollment to day 15 (if a study subject still in the trial)
Number of red blood cell units transfused
Number of allogeneic red blood cell units transfused
Time frame: From enrollment to day 15/death/discharge from ICU/bleeding episode/surgery whatever comes first
Tranfusion rate
Percentage of study subjects receiving at least one red blood cell unit
Time frame: From enrollment to day 15/death/discharge from ICU/bleeding episode/surgery whatever comes first
Deep vein thrombosis prevalence
Number of deep vein thrombosis cases
Time frame: From enrollment to day 15/death/discharge from ICU/bleeding episode/surgery whatever comes first
Pulmonaly embolism prevalence
Number of pulmonary embolism cases
Time frame: From enrollment to day 15/death/discharge from ICU/bleeding episode/surgery whatever comes first
Intensive care unit mortality
Death during intensive care unit hospitalization (index hospitalization)
Time frame: From enrollment to discharge from ICU
30-day mortality
Death within 30 days of day 1
Time frame: From enrollment to day 30
90-day mortality
Death within 90 days of day 1
Time frame: From enrollment to day 90
Actual vs. predicted intensive care unit mortality
Difference between actual intensive care unit mortality and intensive care unit mortality predicted by Sequential Organ Failure Assessment Score (index hospitalization)
Time frame: From enrollment to discharge from ICU
Actual vs. predicted intensive care unit mortality
Difference between actual intensive care unit mortality and intensive care unit mortality predicted by Acute Physiology And Chronic Health Evaluation Score (index hospitalization)
Time frame: From enrollment to discharge from ICU
Actual vs. predicted intensive care unit mortality
Difference between actual intensive care unit mortality and intensive care unit mortality predicted by Simplified Acute Physiology Score III (index hospitalization)
Time frame: From enrollment to discharge from ICU
Plan to share: No — Data privacy issues
Started Nov 2024 (actual). Primary completion is estimated for Dec 2026, 25 months after the start.
Of 60 non-industry phase 4 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 48. This study's planned 25 months is close to that.
Counting every sponsor, half of 74 studies reached it within 25 months; a quarter within 17 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Iron